JP2022523074A5 - - Google Patents
Info
- Publication number
- JP2022523074A5 JP2022523074A5 JP2021544152A JP2021544152A JP2022523074A5 JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5 JP 2021544152 A JP2021544152 A JP 2021544152A JP 2021544152 A JP2021544152 A JP 2021544152A JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798406P | 2019-01-29 | 2019-01-29 | |
| US62/798,406 | 2019-01-29 | ||
| US201962881275P | 2019-07-31 | 2019-07-31 | |
| US62/881,275 | 2019-07-31 | ||
| US201962938415P | 2019-11-21 | 2019-11-21 | |
| US62/938,415 | 2019-11-21 | ||
| PCT/US2020/015723 WO2020160180A1 (en) | 2019-01-29 | 2020-01-29 | Compounds and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523074A JP2022523074A (ja) | 2022-04-21 |
| JPWO2020160180A5 JPWO2020160180A5 (https=) | 2023-02-07 |
| JP2022523074A5 true JP2022523074A5 (https=) | 2023-02-07 |
| JP7665518B2 JP7665518B2 (ja) | 2025-04-21 |
Family
ID=71841237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544152A Active JP7665518B2 (ja) | 2019-01-29 | 2020-01-29 | 化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230079819A1 (https=) |
| EP (1) | EP3917527B1 (https=) |
| JP (1) | JP7665518B2 (https=) |
| CN (1) | CN113645971B (https=) |
| AU (1) | AU2020214308A1 (https=) |
| ES (1) | ES3032327T3 (https=) |
| IL (1) | IL285177B2 (https=) |
| WO (1) | WO2020160180A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| WO2019152437A1 (en) | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2020160100A1 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US20230149414A1 (en) * | 2020-01-29 | 2023-05-18 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CA3167275A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CN115867314A (zh) * | 2020-05-20 | 2023-03-28 | 福宏治疗公司 | 治疗癌症的方法 |
| WO2022079290A2 (en) * | 2020-10-16 | 2022-04-21 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Cullin ring ubiquitin ligase compounds and uses thereof |
| JP2024509268A (ja) | 2021-03-09 | 2024-02-29 | フォグホーン セラピューティクス インコーポレイテッド | 結晶形、それらを含有する組成物、及びそれらの使用方法 |
| WO2022198043A1 (en) * | 2021-03-19 | 2022-09-22 | Foghorn Therapeutics Inc. | Therapeutic regimens of an inhibitor of the enzymatic activity of brg1 and brm |
| WO2023196565A1 (en) * | 2022-04-08 | 2023-10-12 | Foghorn Therapeutics, Inc. | Methods of treating cancer |
| CN119768400A (zh) * | 2022-11-11 | 2025-04-04 | 苏州信诺维医药科技股份有限公司 | 一种稠环化合物、其用途及含其的药物组合物 |
| WO2025082531A1 (en) * | 2023-10-20 | 2025-04-24 | Suzhou Zanrong Pharma Limited | Compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006005941A1 (en) * | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| EP2559455A1 (en) * | 2008-07-15 | 2013-02-20 | Novartis AG | Heteroaryl derivatives as DGAT1 inhibitors |
| CN103429571A (zh) * | 2010-12-22 | 2013-12-04 | 普渡制药公司 | 作为钠通道阻断剂的取代吡啶 |
| JP6554480B2 (ja) * | 2014-03-18 | 2019-07-31 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | オキセパン−２−イル−ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2018187614A1 (en) * | 2017-04-05 | 2018-10-11 | Foghorn Therapeutics | Compounds and uses thereof |
| WO2018213422A1 (en) * | 2017-05-17 | 2018-11-22 | Foghorn Therapeutics | Compounds and uses thereof |
| WO2019152437A1 (en) * | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022508155A (ja) * | 2018-11-21 | 2022-01-19 | フォグホーン セラピューティクス インコーポレイテッド | がんを治療する方法 |
| BR112021010453A2 (pt) | 2018-12-19 | 2021-08-24 | Leo Pharma A/S | Composto, e, composição farmacêutica |
| EA202192101A1 (ru) * | 2019-11-21 | 2021-12-09 | Фогхорн Терапьютикс Инк. | Соединения и их применение |
| EP4097096A4 (en) * | 2020-01-29 | 2024-02-28 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
-
2020
- 2020-01-29 ES ES20749261T patent/ES3032327T3/es active Active
- 2020-01-29 US US17/425,140 patent/US20230079819A1/en active Pending
- 2020-01-29 WO PCT/US2020/015723 patent/WO2020160180A1/en not_active Ceased
- 2020-01-29 IL IL285177A patent/IL285177B2/en unknown
- 2020-01-29 AU AU2020214308A patent/AU2020214308A1/en not_active Abandoned
- 2020-01-29 EP EP20749261.2A patent/EP3917527B1/en active Active
- 2020-01-29 CN CN202080025628.0A patent/CN113645971B/zh active Active
- 2020-01-29 JP JP2021544152A patent/JP7665518B2/ja active Active